Douglas Anthony Pippin
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$6.0MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $6.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 19, 2026 | NIH | SBIR Phase I In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder | $355K | Praeventix, LLC |
| Aug 7, 2024 | NIH | SBIR Phase II IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523 | $728K | Praeventix, LLC |
| May 6, 2024 | NIH | SBIR Phase II In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder | $1.3M | Praeventix, LLC |
| Aug 21, 2023 | NIH | SBIR Phase II IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523 | $1.2M | Praeventix, LLC |
| Jun 24, 2022 | NIH | SBIR Phase I Novel 5-HT7 Antagonists for the Treatment of Pruritus | $276K | Praeventix, LLC |
| May 17, 2022 | NIH | SBIR Phase II In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder | $320K | Praeventix, LLC |
| Sep 3, 2019 | NIH | SBIR Phase I In vivo Characterization of PRA078C in the Rat Cocaine Reinstatement Model | $350K | Praeventix, LLC |
| Jul 23, 2019 | NIH | SBIR Phase II Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease | $1.2M | Praeventix, LLC |
| Aug 10, 2017 | NIH | SBIR Phase I Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease | $232K | Praeventix, LLC |
Peer ranks
Federal funding#189
Awards as PI#151
Patents#273
Companies
- Praeventix, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.